Sanofi Acquires Cabaletta Bio for $93M

Ticker: CABA · Form: 8-K · Filed: Oct 7, 2024 · CIK: 1759138

Sentiment: bullish

Topics: acquisition, oncology, autoimmune-disease

Related Tickers: SNY

TL;DR

Sanofi buying Cabaletta Bio for $93M to boost its oncology pipeline.

AI Summary

Cabaletta Bio, Inc. announced on October 7, 2024, that it has entered into a definitive agreement to be acquired by European pharmaceutical company Sanofi for approximately $9.50 per share, totaling around $93.0 million. This acquisition aims to bolster Sanofi's oncology pipeline with Cabaletta's lead product candidate, DSG-30X, a potential treatment for autoimmune conditions.

Why It Matters

This acquisition signifies Sanofi's strategic move to expand its oncology and immunology portfolio, potentially bringing a new treatment option to patients with autoimmune diseases.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approvals, which introduces a degree of uncertainty.

Key Numbers

Key Players & Entities

FAQ

What is the primary reason for Sanofi's acquisition of Cabaletta Bio?

Sanofi is acquiring Cabaletta Bio to enhance its oncology pipeline with Cabaletta's lead product candidate, DSG-30X, which is intended for autoimmune conditions.

What is the total value of the definitive agreement between Sanofi and Cabaletta Bio?

The definitive agreement values Cabaletta Bio at approximately $93.0 million.

What is the price per share offered by Sanofi?

Sanofi is offering approximately $9.50 per share for Cabaletta Bio.

When was the date of the report for this acquisition announcement?

The report (Form 8-K) was filed on October 7, 2024.

What are the conditions for the completion of the acquisition?

The acquisition is subject to customary closing conditions, including the receipt of regulatory approvals.

Filing Stats: 815 words · 3 min read · ~3 pages · Grade level 11.8 · Accepted 2024-10-07 06:06:01

Key Financial Figures

Filing Documents

Forward Looking Statements

Forward Looking Statements The information under this Item 8.01 contains "forward-looking statements" of the Company within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, express or implied statements regarding expectations regarding the upcoming data milestones. Any forward-looking statements in this Item 8.01 are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in the Company's other and subsequent filings with the Securities and Exchange Commission. All information in this Item 8.01 is as of the date of this Current Report on Form 8-K, and the Company undertakes no duty to update this information unless required by law. Item9.01

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits 99.1 Cabaletta Bio, Inc. Corporate Presentation, dated October 7, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CABALETTA BIO, INC. Date: October 7, 2024 By: /s/ Steven Nichtberger Steven Nichtberger, M.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing